Search

SWG Educational Activities

MeetingsSession on thrombocytopenias and platelet function disordersAt the EHA 2023 Congress, we held a session on ‘Thrombocytopenias and platelet function disorders: Recent developments and perspectives in immune thrombocytopenia.

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies, scheduled to be held on October 18-20, 2024 in Tbilisi, Georgia.…

Read more

“Nothing about us without us”: how patient advocacy is changing the game

Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) MENA 2023, to be held on November 4, 2023 in Antalya, Türkiye.

Read more

Sponsors

If you want to go fast, go alone. If you want to go far, go together. We aim for long-term relationships with our partners and sponsors.

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) Latin America (LA) 2023, to be held on October 26, 2023 in São Paulo, Brazil.

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-KCS Hematology Tutorial – Recent Advances in Lymphoid and Myeloid Malignancies, scheduled to be held on September 14-15, 2024 in Almaty, Kazakhstan.

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-TSH Hematology Tutorial on T Cell Lymphomas, scheduled to be held on June 29-30, 2024 in Ankara, Türkiye.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more